Regulatory 2022-12-06 | New Strong Orviglance Data Support Successful SPARKLE Completion with Substantially Fewer Patients PDF Report Financial Data Presentation Webcast
Regulatory 2022-03-07 | Ascelia Pharma suspends clinical activities in Russia PDF Report Financial Data Presentation Webcast
Regulatory 2021-09-21 | Ascelia Pharma Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the Development of Oncoral in Combination with LONSURF® PDF Report Financial Data Presentation Webcast
Regulatory 2021-08-18 | Covid-19 extends recruitment period of SPARKLE study PDF Report Financial Data Presentation Webcast
Regulatory 2021-03-17 | Ascelia Pharma has carried out a directed new share issue raising SEK 200 million PDF Report Financial Data Presentation Webcast
Regulatory 2021-03-17 | Ascelia Pharma intends to carry out a directed new share issue PDF Report Financial Data Presentation Webcast
Regulatory 2020-12-15 | Ascelia Pharma gets US patent for second generation Mangoral PDF Report Financial Data Presentation Webcast
Regulatory 2020-12-02 | New study shows Mangoral’s lesion visualization as effective as gadolinium contrast agent PDF Report Financial Data Presentation Webcast
Regulatory 2020-10-21 | Upgraded estimate of addressable market for Mangoral to $500-600 million annually PDF Report Financial Data Presentation Webcast
Regulatory 2020-05-20 | Updated SPARKLE timelines due to Covid-19 impact PDF Report Financial Data Presentation Webcast
Regulatory 2020-05-06 | First participant enrolled in the clinical hepatic impairment study with Mangoral PDF Report Financial Data Presentation Webcast
Regulatory 2020-02-19 | First patient enrolled in pivotal Phase III clinical study SPARKLE with lead candidate Mangoral PDF Report Financial Data Presentation Webcast
Regulatory 2019-06-10 | Ascelia Pharma strengthens its Mangoral franchise by filing of a patent application for next generation Mangoral product PDF Report Financial Data Presentation Webcast
Regulatory 2019-05-07 | Ascelia Pharma received supportive feedback from EMA on the phase 3 program for Mangoral® PDF Report Financial Data Presentation Webcast
Regulatory 2019-04-12 | Exercise of over-allotment option, stabilisation notice and end of the stabilisation period PDF Report Financial Data Presentation Webcast
Regulatory 2019-04-08 | Encouraging results from the Phase I combination study with Oncoral and oral capecitabine published in the journal Cancer Chemotherapy and Pharmacology PDF Report Financial Data Presentation Webcast
